Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was -13.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 1.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Scholar Rock Holding was 11.80% per year. The lowest was -30.30% per year. And the median was -4.50% per year.
Scholar Rock Holding (FRA:2QK) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Scholar Rock Holding 3-Year EBITDA Growth Rate Related Terms
FRA:2QK vs CAI, RYTM, CGON: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Scholar Rock Holding's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's 3-Year EBITDA Growth Rate falls into.
Scholar Rock Holding 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -13.50% mean?
Scholar Rock Holding (FRA:2QK) has a 3-Year EBITDA Growth Rate of -13.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Scholar Rock Holding and its competitors. According to the industry distribution chart, Scholar Rock Holding ranks #910 out of 1124 companies in the Biotechnology industry, placing it in the top 81%.
Is Scholar Rock Holding's 3-Year EBITDA Growth Rate too high?
Scholar Rock Holding's current 3-Year EBITDA Growth Rate is -13.50%. Based on the distribution chart, Scholar Rock Holding ranks #910 out of 1124 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's 3-Year EBITDA Growth Rate compare to CAI and RYTM?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #910 out of 1124 companies for 3-Year EBITDA Growth Rate. This places Scholar Rock Holding in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Scholar Rock Holding and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scholar Rock Holding's current 3-Year EBITDA Growth Rate is -13.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Based on GuruFocus' analysis, Scholar Rock Holding (FRA:2QK) is currently considered Significantly Overvalued. The stock's GF Value™ is €25.26, compared to a current price of €42.37 — trading 67.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -13.50%. Scholar Rock Holding's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current 3-Year EBITDA Growth Rate is -13.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scholar Rock Holding (FRA:2QK) Overvalued in 2026?
Based on GuruFocus' analysis, Scholar Rock Holding stock appears to be overvalued.
The current stock price of €42.37 is trading 67.7% above its estimated GF Value™ of €25.26.
GuruFocus considers Scholar Rock Holding to be Significantly Overvalued.
Key valuation signals for FRA:2QK:
3-Year EBITDA Growth Rate: -13.50%
GF Value™: €25.26 vs. price of €42.37 (67.7% above fair value)
No single metric tells the full story. See the FRA:2QK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
48GF Score
Get the complete analysis for FRA:2QK
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
